الفهرس 
End stage renal disease (renal failure)Only 14 pages are availabe for public view
 |  | from | 168 |  |  |
| | | from | 168 | | |
Abstract
ABSTRACT
Background: Anemia is a prevalent symptom of ESKD and is associated with an increased risk of hospitalization and mortality. Anemia is defined as a lack of erythropoietin production, decreased red blood cell survival, and blood loss from the dialysis circuit.
Aim of the Work: The goal of this study is to determine the efficacy of oral ascorbic acid (AA) in treating anemia in persons with ESKD who also have elevated ferritin levels.
Patients and Methods: 50 patients with early-stage kidney disease (ESKD) who underwent standard HD were divided into two groups: group A (25 patients) received oral ascorbic acid 250 mg once daily for six months along with iron supplementation, while group B (25 patients of the same age and sex) received oral ascorbic acid without iron supplementation.
Results: group A (combined vitamin C and iron) exhibited considerably increased transferrin saturation after 3 and 6 months of treatment. At 3 and 6 months following treatment, transferrin saturation increased in individuals in group A (combined vitamin C and iron) compared to baseline.
Conclusion: The current study’s findings suggest that anemia is a common concern among ESRD patients, particularly those on hemodialysis. Iron a